1. Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl) 1990;102:474–478. PMID:
1982902.
2. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981;138:1618–1619. PMID:
6118067.
3. Tarsy D, Baldessarini RJ. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977;12:431–450. PMID:
194633.
4. Casey DE, Gerlach , Magelund G, Christensen TR. gamma-Acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376–1379. PMID:
6108751.
5. Andreassen OA, Jørgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525–541. PMID:
10748322.
6. Flatmark T, Stevens RC. Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem Rev 1999;99:2137–2160. PMID:
11849022.
7. Kobayashi K, Nagatsu T. Molecular genetics of tyrosine 3-monooxygenase and inherited diseases. Biochem Biophys Res Commun 2005;338:267–270. PMID:
16105653.
8. Lüdecke B, Bartholomé K. Frequent sequence variant in the human tyrosine hydroxylase gene. Hum Genet 1995;95:716PMID:
7789962.
9. Salvatore MF, Waymire JC, Haycock JW. Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 2001;79:349–360. PMID:
11677263.
10. Zivkovic B, Guidotti A, Revuelta A, Costa E. Effect of thioridazine, clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens. J Pharmacol Exp Ther 1975;194:37–46. PMID:
239221.
11. Håkansson K, Pozzi L, Usiello A, Haycock J, Borrelli E, Fisone G. Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur J Neurosci 2004;20:1108–1112. PMID:
15305880.
12. Ankenman R, Salvatore MF. Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. J Neuropsychiatry Clin Neurosci 2007;19:65–69. PMID:
17308229.
13. Han OS, Hong JP. Structured Clinical Interview for DSM-IV Axis I Disorder-Korean Version. 2000,Seoul: Hana Medical Publishing.
14. Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007;55:47–51. PMID:
17556853.
15. Lee HJ, Kang SG, Paik JW, Lee MS, Cho BH, Park YM, et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007;22:501–504. PMID:
17726725.
16. Kang SG, Choi JE, An H, Lim SW, Lee HJ, Han C, et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1545–1548. PMID:
18602732.
17. Kang SG, Choi JE, Park YM, Lee HJ, Han C, Kim YK, et al. Val158-Met polymorphism in the catechol-O-methyltransferase (COMT) gene is not associated with tardive dyskinesia in schizophrenia. Neuropsychobiology 2008;57:22–25. PMID:
18424907.
18. Kang SG, Choi JE, An H, Park YM, Lee HJ, Han C, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1844–1847. PMID:
18790709.
19. Kang SG, Lee HJ, Choi JE, An H, Rhee M, Kim L. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009;24:55–60. PMID:
19051221.
20. Guy W. Abnormal Involuntary Movement Scale (AIMS); ECDEU assessment manual for psychopharmacology. 1976,Rockville, MD: U.S. Dept. of Health, Education and Welfare; p. 534–537.
21. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486–487. PMID:
6121550.
22. Ota M, Nakashima A, Ikemoto K, Nojima S, Tanaka M, Okuda M, et al. Exon 3 of tyrosine hydroxylase gene: lack of association with Japanese schizophrenic patients. Mol Psychiatry 2001;6:315–319. PMID:
11326301.
23. Bloomquist J, King E, Wright A, Mytilineou C, Kimura K, Castagnoli K, et al. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J Pharmacol Exp Ther 1994;270:822–830. PMID:
8071874.
24. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P, Gessa GL, et al. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur J Neurosci 2002;15:1187–1196. PMID:
11982629.
25. Lerner P, Nosé P, Gordon EK, Lovenberg W. Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science 1977;197:181–183. PMID:
17917.
26. Albanése V, Biguet NF, Kiefer H, Bayard E, Mallet J, Meloni R. Quantitative effects on gene silencing by allelic variation at a tetranucleotide microsatellite. Hum Mol Genet 2001;10:1785–1792. PMID:
11532988.
27. Kunugi H, Kawada Y, Tatsumi M, Sasaki T, Nanko S. Manic-depressive illness and tyrosine hydroxylase gene. Lancet 1996;348:336PMID:
8709706.
28. Han GR, Lee YW, Lee HL, Kim SM, Ku TW, Kang IH, et al. A Korean population study of the nine STR loci FGA, VWA, D3S1358, D18S51, D21S11, D8S1179, D7S820, D13S317 and D5S818. Int J Legal Med 2000;114:41–44. PMID:
11197626.